Showing 6031-6040 of 20929 results for "".
- Mapping the Molecular Landscape of MS: A Multiomics Approach Uncovers New Drug Targetshttps://reachmd.com/news/multiple-sclerosis-new-potential-drug-targets-for-improved-treatment/2475477/Despite decades of research, multiple sclerosis (MS) remains an incurable, immune-mediated neurological disease, particularly resistant to treatment in its progressive forms. Now, a large-scale study</
- Neutrophil-to-HDL Ratio: A New Frontier in Predicting Hematoma Expansionhttps://reachmd.com/news/neutrophil-to-hdl-ratio-a-new-frontier-in-predicting-hematoma-expansion/2475446/Emergency teams and stroke neurologists confront a critical blind spot in spontaneous intracerebral hemorrhage: up to one-third of patients experience significant h
- Obinutuzumab's Role in Lupus Nephritis: Shifting Treatment Paradigmshttps://reachmd.com/news/obinutuzumabs-role-in-lupus-nephritis-shifting-treatment-paradigms/2475447/Lupus nephritis persists as a therapy-resistant condition, underscoring the urgency for new treatments. Obinutuzumab emerges as a novel adjunct to conventional immunosuppression, poised to shift practice standards in line with the latest EULA
- Revolutionizing Prostate Cancer Care: Emerging Non-Chemotherapy Treatmentshttps://reachmd.com/news/revolutionizing-prostate-cancer-care-emerging-non-chemotherapy-treatments/2475441/Metastatic prostate cancer has traditionally relied on chemotherapy, imposing substantial burdens on patients; recent non-chemotherapy strategies and targeted agents now offer fresh therapeutic avenues. Clinicians managing metastatic c
- Cross-Specialty Care Enhances Remission Rates in Rheumatoid Arthritishttps://reachmd.com/news/innovative-cross-specialty-care-enhances-remission-rates-in-rheumatoid-arthritis/2475442/Recent data from Cedars-Sinai’s Inflammatory Arthritis Clinical Care Center revealed a 30% relative increase in remission rate at 12 months among rheumatoid arthritis (RA) patients managed through a coordinated, cross-specialty team compared
- Durvalumab Revolutionizes Perioperative Bladder Cancer Treatmenthttps://reachmd.com/news/durvalumab-revolutionizes-perioperative-bladder-cancer-treatment/2475418/The recent Durvalumab approved for perioperative bladder cancer use represents a significant advance in muscle-invasive bladder cancer management, providing a neoadjuvant strategy that
- Monoclonal Antibodies: Transforming RSV Prevention in Pediatricshttps://reachmd.com/news/monoclonal-antibodies-transforming-rsv-prevention-in-pediatrics/2475421/RSV continues to drive substantial infant hospitalizations each winter, with about 58,000 to 80,000 children under five years hospitalized annually in the U.S. RSV proph
- The Role of FOXA1 Mutations in Prostate Cancer Resistancehttps://reachmd.com/news/the-role-of-foxa1-mutations-in-prostate-cancer-resistance/2475435/Recent studies have demonstrated that FOXA1 mutations contribute to prostate tumor growth and therapeutic resistance, suggesting a potential shift toward precision-targeted interventions. However, further research is needed to fully establish
- Evolving Prostate Cancer Therapies: Reducing Toxicity in Treatment Regimenshttps://reachmd.com/news/evolving-prostate-cancer-therapies-reducing-toxicity-in-treatment-regimens/2475427/Oncologists confronting metastatic castration-sensitive prostate cancer are increasingly favoring therapies that spare patients the toxicity of traditional cytotoxic regimens, reshaping treatment algorithms and quality of life expectations.</
- Exploring the Gut-Lung Axis: New Frontiers in COVID-19 Therapeuticshttps://reachmd.com/news/exploring-the-gut-lung-axis-new-frontiers-in-covid-19-therapeutics/2475394/While current research on the gut-lung axis underscores its potential to influence COVID-19 therapeutics by showing that gut microbes can modulate respiratory immunity, most evidence is derived from preclinical studies, highl